Psoriasis Gene-Edited Cell Lines for Drug Discovery

Psoriasis is a chronic, immune-mediated inflammatory skin disease affecting approximately 2-3% of the global population, with prevalence varying by region (e.g., 0.5% in East Asia to 8.5% in Norway) (WHO Global Report on Psoriasis, 2016). The disease significantly impacts quality of life, with up to 30% of patients developing psoriatic arthritis. Psoriasis is associated with comorbidities including cardiovascular disease, diabetes, and depression. While not directly fatal, severe psoriasis can reduce life expectancy by 4-5 years. The economic burden is substantial, with annual direct and indirect costs in the US exceeding $135 billion (NCI SEER data, 2023).

Psoriasis is an ideal model for studying chronic inflammation, keratinocyte hyperproliferation, and immune dysregulation. Key subtypes include plaque psoriasis (90% of cases), guttate, inverse, pustular, and erythrodermic. Public datasets such as the Psoriasis Transcriptome Project (GEO) and the Human Cell Atlas provide rich resources. Open questions include the role of tissue-resident memory T cells, the interplay between genetic susceptibility (e.g., HLA-Cw6, IL23R) and environmental triggers, and the mechanisms of response to biologics. Gene-edited cell models enable precise dissection of these pathways.

Psoriasis is driven by a dysregulated immune response involving the IL-23/Th17 axis. The key steps are:

1. Activation of dendritic cells by self-DNA/LL37 complexes, leading to IL-23 production.

2. IL-23 promotes Th17 cell differentiation and IL-17A, IL-17F, and IL-22 secretion.

3. IL-17A acts on keratinocytes, inducing proliferation and production of chemokines (CXCL1, CXCL8) and antimicrobial peptides (S100A7, beta-defensins).

4. Positive feedback loop: keratinocyte-derived cytokines (TNF-alpha, IL-1beta) further activate dendritic cells and T cells.

5. STAT3 signaling in keratinocytes drives hyperproliferation and inhibits apoptosis.

6. Angiogenesis via VEGF and angiopoietins supports the psoriatic plaque.

Psoriasis is polygenic, with multiple risk loci identified through GWAS. The following table summarizes key susceptibility genes and their functional impact.

Data from NCBI Gene, GWAS Catalog, and meta-analyses.

Key signaling networks in psoriasis include:

• • IL-23/Th17 axis: Central to disease pathogenesis. IL-23 binds IL-23R, activating JAK2/STAT3 in Th17 cells, leading to IL-17 production.
• • IL-17 signaling: IL-17A binds IL-17RA/RC, activating NF-kB, MAPK, and C/EBP pathways in keratinocytes.
• • TNF-alpha signaling: TNFR1/2 activation leads to NF-kB and AP-1, promoting inflammation and keratinocyte survival.
• • JAK-STAT pathway: JAK1/2 and TYK2 mediate cytokine signaling; STAT3 is a key transcription factor in keratinocyte proliferation.
• • NF-kB pathway: Central to innate immune responses; activated by TNF-alpha, IL-1beta, and TLR ligands.
• • MAPK/ERK pathway: Drives keratinocyte proliferation; activated by growth factors and cytokines.
• • PI3K/AKT/mTOR pathway: Promotes cell survival and protein synthesis; hyperactive in psoriatic lesions.

The following table lists commonly used cell lines for psoriasis research.

Organoids derived from psoriatic patient skin recapitulate the disease microenvironment, including immune cell infiltration and cytokine signaling. They are superior for studying cell-cell interactions and drug responses.

Animal models for psoriasis include:

• • Imiquimod-induced mouse model: Topical imiquimod activates TLR7, inducing psoriasiform dermatitis with IL-23/Th17 involvement.
• • Xenotransplantation (PDX): Human psoriatic skin grafted onto immunodeficient mice (e.g., NSG) allows study of human immune responses.
• • Genetically engineered mouse models (GEMM):
• • K14-STAT3C transgenic mice: Constitutive STAT3 activation in keratinocytes leads to spontaneous psoriasis-like lesions.
• • K5-IL-17A transgenic mice: Overexpression of IL-17A in epidermis induces skin inflammation.
• • CD18 hypomorphic mice: Reduced beta2 integrin expression leads to psoriasiform dermatitis.
• • Induced models: Aldara cream (imiquimod) is the most widely used acute model.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications, such as knockout (KO), knock-in (KI), or point mutations. For psoriasis research, examples include:

• • IL-17A KO in HaCaT cells: Disrupts IL-17 signaling, allowing study of downstream effects on keratinocyte proliferation and chemokine production.
• • STAT3 KO in NHEK cells: Ablates STAT3 signaling, revealing its role in cytokine-induced hyperproliferation.
• • IL23R KO in T cell lines: Blocks IL-23 signaling, enabling investigation of Th17 differentiation.
• • TNIP1 KO in keratinocytes: Mimics loss-of-function risk variants, leading to enhanced NF-kB activation.
• • LCE3B/LCE3C deletion models: Recapitulate barrier dysfunction seen in psoriasis patients.

Commercially available, sequence-verified, and mycoplasma-free gene-edited cell models accelerate research by providing reproducible, isogenic controls. These models are validated by Sanger sequencing and functional assays, ensuring reliability for drug screening and target validation.

Gene-edited cell lines are essential for validating the functional role of psoriasis risk genes. For example:

• • IL-17A KO in HaCaT cells: Confirms that IL-17A is required for keratinocyte production of CXCL8 and S100A7, key mediators of neutrophil recruitment and antimicrobial defense.
• • STAT3 KO in NHEK cells: Demonstrates that STAT3 is necessary for IL-22-induced keratinocyte proliferation and migration.
• • TNIP1 KO in keratinocytes: Shows that loss of TNIP1 enhances TNF-alpha-induced NF-kB activation and pro-inflammatory cytokine production.
• • LCE3B KO in organoids: Reveals impaired barrier function and increased susceptibility to microbial triggers.

Isogenic cell line pairs (e.g., wild-type vs. IL-17A KO) enable high-throughput screening for compounds that target specific pathways. Applications include:

• • Screening for novel IL-17 inhibitors using IL-17A KO cells as a negative control.
• • Identifying resistance mechanisms by exposing STAT3 KO cells to JAK inhibitors and monitoring compensatory pathways.
• • Testing combination therapies: For example, using TNIP1 KO cells to evaluate synergy between TNF-alpha inhibitors and NF-kB blockers.
• • Modeling drug resistance: Chronic exposure of HaCaT cells to methotrexate or biologics can select for resistant clones, which can be analyzed by whole-genome sequencing.

CRISPR screens in psoriasis-relevant cell lines can identify synthetic lethal interactions and novel biomarkers. Examples:

• • Genome-wide CRISPR KO screen in HaCaT cells treated with IL-17A: Identifies genes whose loss sensitizes cells to IL-17A-induced apoptosis, revealing potential therapeutic targets.
• • CRISPR activation (CRISPRa) screen for genes that rescue IL-17A KO phenotype: Uncovers compensatory pathways.
• • Secretome analysis of TNIP1 KO vs. wild-type keratinocytes: Identifies secreted proteins (e.g., IL-36, CXCL10) that could serve as serum biomarkers for disease activity.